David Bonita

David P.
Bonita currently serves as Independent Director at Acutus Medical, Inc. since 2016, Lead Independent Director at ImageneBio, Inc. starting in 2025, Independent Director at Prelude Therapeutics, Inc. since 2016, Independent Director at Third Harmonic Bio, Inc. since 2020, Director at Treeline Biosciences, Inc., General Partner at OrbiMed Advisors Private Equity since 2020, Member at Orbimed Private Investments VII LP, and Secretary at Auraeda, Inc. since 2021.
Former roles include Chairman at Clementia Pharmaceuticals, Inc. from 2014 to 2019, Independent Director at Ambit Biosciences Corp.
from 2012 to 2014, Independent Non-Executive Director at ViewRay Technologies, Inc., Director at Edwards Lifesciences CardiaQ LLC, Independent Director at SI-BONE, Inc. from 2014 to 2019, Independent Director at ViewRay, Inc. from 2015 to 2018, Independent Director at Tricida, Inc. from 2014 to 2023, Independent Director at Repare Therapeutics, Inc. from 2019 to 2026, Director at Enobia Pharma, Inc., Director at Imaxio SA, Director at Keystone Heart Ltd., Director at Sublimity Therapeutics Ltd., Independent Director at Loxo Oncology, Inc. from 2013 to 2017, Independent Director at Ikena Oncology, Inc., Independent Director at Imara, Inc., Director at Cryterion Medical, Inc., Finance Analyst at Morgan Stanley, and Finance Analyst at UBS Securities LLC.
Education includes an MBA and doctorate from The Trustees of Columbia University in The City of New York, both conferred in 2004, and an undergraduate degree from Harvard University conferred in 1997.